Cited by 1,379Chronic Lymphocytic Leukemia ResearchCancer Genomics and DiagnosticsAcute Myeloid Leukemia Research

Evolution and impact of subclonal mutations in chronic lymphocytic leukemia

Open access
Landau, Dan A., Carter, Scott L., Stojanov, Petar, McKenna, Aaron, Stevenson, Kristen, Lawrence, Michael S., Sougnez, Carrie, Stewart, Chip +18 more·2013·Cell

Abstract

Clonal evolution is a key feature of cancer progression and relapse. We studied intratumoral heterogeneity in 149 chronic lymphocytic leukemia (CLL) cases by integrating whole-exome sequence and copy number to measure the fraction of cancer cells harboring each somatic mutation. We identified driver mutations as predominantly clonal (e.g., MYD88, trisomy 12, and del(13q)) or subclonal (e.g., SF3B1 and TP53), corresponding to earlier and later events in CLL evolution. We sampled leukemia cells from 18 patients at two time points. Ten of twelve CLL cases treated with chemotherapy (but only one of six without treatment) underwent clonal evolution, predominantly involving subclones with driver mutations (e.g., SF3B1 and TP53) that expanded over time. Furthermore, presence of a subclonal driver mutation was an independent risk factor for rapid disease progression. Our study thus uncovers patterns of clonal evolution in CLL, providing insights into its stepwise transformation, and links the presence of subclones with adverse clinical outcomes.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2013.01.019

Cites

77 of 77 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Several recent studies have shown a similar spectrum of genetic alterations to those observed here during the somatic evolution of cancers in patients undergoing chemotherapy or treated with specific inhibitors.

    “Indeed, several recent studies have shown a similar spectrum of genetic alterations to those observed here during the somatic evolution of cancers in patients undergoing chemotherapy (Podlaha et al., 2012; Landau et al., 2013) or treated with specific inhibitors (Ding et al., 2012) to those observed here.”

    From The evolution of drug resistance in clinical isolates of Candida albicans. (2015) · cites this paper as Landau et al., 2013

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Landau, D. A., Carter, S. L., Stojanov, P., McKenna, A., Stevenson, K., Lawrence, M. S., Sougnez, C., Stewart, C., Sivachenko, A., Wang, L., Wan, Y., Zhang, W., Shukla, S. A., Vartanov, A., Fernandes, S. M., Saksena, G., Cibulskis, K., Tesar, B., Gabriel, S., Hacohen, N., Meyerson, M., Lander, E. S., Neuberg, D., Brown, J. R., Getz, G., & Wu, C. J.
Affiliations
  • Broad Institute (US)
  • Dana-Farber Cancer Institute (US)
  • Brigham and Women's Hospital (US)
Corresponding author
  • Getz, Gad
  • Wu, Catherine J.
Venue
Cell
Publisher
Elsevier BV
Published
2013-02
Volume
152
Issue
4
Pages
714-726
ISSN
0092-8674 (ISSN-L)
OpenAlex
W2088580309
Cited by
1,379
References
77
Citations by year
2026: 29 · 2025: 38 · 2024: 47 · 2023: 70 · 2022: 94 · 2021: 110 · 2020: 86 · 2019: 103 · 2018: 134 · 2017: 133 · 2016: 156 · 2015: 144 · 2014: 147 · 2013: 85 · 2012: 1
FWCI
87.31
Type
journal article
Language
en
Open access
Locations
  • Cell (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
  • DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
Funders
  • National Heart, Lung, and Blood Institute (R01HL103532)
  • National Human Genome Research Institute (U54HG003067)
  • National Cancer Institute (K23CA115682, R01CA155010)
Topics
  • Health Sciences › Medicine › Genetics › Chronic Lymphocytic Leukemia Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
  • Health Sciences › Medicine › Hematology › Acute Myeloid Leukemia Research
Keywords
chronic lymphocytic leukemia, clonal evolution, subclonal mutations, intratumoral heterogeneity, driver mutations, SF3B1, TP53, MyD88, trisomy 12, del(13q), copy number alterations, disease progression, chemotherapy, clonal expansion
MeSH terms
Algorithms, Animals, B-Lymphocytes, Humans, Mutation, Ploidies, Leukemia, Lymphocytic, Chronic, B-Cell, Genome-Wide Association Study, DNA Copy Number Variations

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review